Sorafenib plus drug-eluting bead transarterial chemoembolization for early intrahepatic stage-progressed advanced hepatocellular carcinoma refractory to conventional transarterial chemoembolization

[1]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[2]  Yulei N. Wang,et al.  Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. , 2020, The New England journal of medicine.

[3]  Versione,et al.  Common Terminology Criteria for Adverse Events , 2020, Definitions.

[4]  Jianwei Xu,et al.  Safety and Efficacy of Drug-Eluting Bead Transarterial Chemoembolization Combined with Apatinib in Patients with Advanced Hepatocellular Carcinoma. , 2020, Academic radiology.

[5]  M. Kudo,et al.  Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial , 2019, Gut.

[6]  M. Kudo,et al.  FRI-494-Practice patterns and outcomes of transarterial chemoembolization in patients with hepatocellular carcinoma who were ineligible and eligible for transarterial chemoembolization at inclusion: Global OPTIMIS exploratory analysis , 2019, Journal of Hepatology.

[7]  Bo Hyun Kim,et al.  Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial. , 2019, Journal of hepatology.

[8]  Cong Ma,et al.  Safety and efficacy assessment of transarterial chemoembolization using drug-eluting beads in patients with hepatocellular carcinoma and arterioportal shunt: a single-center experience , 2019, Cancer management and research.

[9]  P. Schirmacher,et al.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.

[10]  M. Kudo,et al.  Real-world data in patients with hepatocellular carcinoma treated with transarterial chemoembolization: the second interim analysis of OPTIMIS , 2018 .

[11]  M. Kudo,et al.  Deterioration of liver function after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): An exploratory analysis of OPTIMIS—An international observational study assessing the use of sorafenib after TACE. , 2018 .

[12]  Lequn Li,et al.  The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma , 2017, BMC Cancer.

[13]  D. Stocken,et al.  Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. , 2017, The lancet. Gastroenterology & hepatology.

[14]  M. Kudo,et al.  Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications , 2017, Liver Cancer.

[15]  R. Lencioni,et al.  Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data , 2016, Hepatology.

[16]  M. Imamura,et al.  Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization. , 2016, Anticancer research.

[17]  Riccardo Lencioni,et al.  Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. , 2016, Journal of hepatology.

[18]  M. Kudo,et al.  Subclassification of BCLC B Stage Hepatocellular Carcinoma and Treatment Strategies: Proposal of Modified Bolondi's Subclassification (Kinki Criteria) , 2015, Digestive Diseases.

[19]  F. Hucke,et al.  Transarterial chemoembolization: modalities, indication, and patient selection. , 2015, Journal of hepatology.

[20]  S. Paik,et al.  Changes in Arterioportal Shunts in Hepatocellular Carcinoma Patients with Portal Vein Thrombosis Who Were Treated with Chemoembolization Followed by Radiotherapy , 2014, Cancer research and treatment : official journal of Korean Cancer Association.

[21]  Y. Imai,et al.  JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan , 2014, Liver Cancer.

[22]  H. Shan,et al.  Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib--a retrospective controlled study. , 2014, Radiology.

[23]  H. Ueno,et al.  Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization , 2014, Journal of Gastroenterology.

[24]  Myeong Jun Song,et al.  DC Bead Transarterial Chemoembolization Is Effective in Hepatocellular Carcinoma Refractory to Conventional Transarteral Chemoembolization: A Pilot Study , 2013, Gut and liver.

[25]  Joong-Won Park,et al.  Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. , 2012, Journal of hepatology.

[26]  J. Joo,et al.  Severity and timing of progression predict refractoriness to transarterial chemoembolization in hepatocellular carcinoma , 2012, Journal of gastroenterology and hepatology.

[27]  D. Sze,et al.  Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. , 2012, Journal of vascular and interventional radiology : JVIR.

[28]  S. Hori,et al.  Switching the Loaded Agent from Epirubicin to Cisplatin: Salvage Transcatheter Arterial Chemoembolization with Drug-eluting Microspheres for Unresectable Hepatocellular Carcinoma , 2012, CardioVascular and Interventional Radiology.

[29]  T. Pawlik,et al.  Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  T. Vogl,et al.  Transcatheter Treatment of Hepatocellular Carcinoma with Doxorubicin-loaded DC Bead (DEBDOX): Technical Recommendations , 2011, CardioVascular and Interventional Radiology.

[31]  T. Vogl,et al.  Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. , 2010, AJR. American journal of roentgenology.

[32]  Riccardo Lencioni,et al.  Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.

[33]  T. Vogl,et al.  Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indications. , 2009, European journal of radiology.

[34]  T. Vogl,et al.  Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study , 2009, CardioVascular and Interventional Radiology.

[35]  J. Bruix,et al.  Management of hepatocellular carcinoma , 2005, Hepatology.

[36]  K. Sung,et al.  Recurrences of hepatocellular carcinoma following initial remission by transcatheter arterial chemoembolization 1 , 2002, Journal of gastroenterology and hepatology.

[37]  H. Niitani,et al.  [Phase II study]. , 1995, Gan to kagaku ryoho. Cancer & chemotherapy.

[38]  N. Dobbs,et al.  Pharmacokinetics and toxicity of intraarterial adriamycin for hepatocellular carcinoma: effect of coadministration of lipiodol. , 1991, Journal of hepatology.